Pluristem prices $32m offering to progress stem cell therapies
This article was originally published in Scrip
Executive Summary
Allogeneic stem cell therapy developer Pluristem Therapeutics priced an offering of eight million units - each consisting of one share of common stock share and a warrant to purchase 35% of one share - at $4 per unit for gross proceeds of $32 million to finance research and development, including clinical trials.